Neuropsychological decline up to 20 years before incident mild cognitive impairment

[1]  S. Leurgans,et al.  Attributable risk of Alzheimer's dementia attributed to age‐related neuropathologies , 2018, Annals of neurology.

[2]  Nick C. Fox,et al.  Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease , 2018, Neurology.

[3]  R. Petersen,et al.  APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology , 2018, Neurology.

[4]  D. Collerton,et al.  Reduced occipital GABA in Parkinson disease with visual hallucinations , 2018, Neurology.

[5]  S. Reeves,et al.  The neurochemistry of agitation in Alzheimer’s disease: a systematic review , 2018, Ageing Research Reviews.

[6]  Travis A. Johnson,et al.  Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment , 2018, Journal of the American Geriatrics Society.

[7]  Frederik Barkhof,et al.  Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts , 2017, Alzheimer's & Dementia.

[8]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[9]  D. Bennett,et al.  Outcomes after diagnosis of mild cognitive impairment in a large autopsy series , 2017, Annals of neurology.

[10]  Alan J. Thomas,et al.  Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations , 2016, Acta neuropathologica communications.

[11]  Travis A. Johnson,et al.  Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment , 2015, BMC Neurology.

[12]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[13]  A. Fleisher,et al.  The neuropsychology of normal aging and preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[14]  D. Knopman,et al.  Depressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study. , 2013, The Journal of clinical psychiatry.

[15]  Janet B W Williams.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[16]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[17]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[18]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[19]  E G Tangalos,et al.  The incidence of MCI differs by subtype and is higher in men , 2012, Neurology.

[20]  L. McEvoy,et al.  Predicting MCI outcome with clinically available MRI and CSF biomarkers , 2011, Neurology.

[21]  T. Goldberg,et al.  Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. , 2011, Archives of general psychiatry.

[22]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[24]  E G Tangalos,et al.  Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.

[25]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[26]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[27]  Sirkka Goebeler,et al.  Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.

[28]  A. Saykin,et al.  Differential Memory Test Sensitivity for Diagnosing Amnestic Mild Cognitive Impairment and Predicting Conversion to Alzheimer's Disease , 2009, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[29]  L. Baxter,et al.  Assessment of Patient and Caregiver Experiences of Dementia-Related Symptoms: Development of the Multidimensional Assessment of Neurodegenerative Symptoms Questionnaire , 2009, Dementia and Geriatric Cognitive Disorders.

[30]  Richard L. Doty,et al.  Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease , 2008, Biological Psychiatry.

[31]  G. Alexander,et al.  Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. , 2008, Archives of neurology.

[32]  Eric M Reiman,et al.  Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. , 2007, Archives of neurology.

[33]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[34]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[35]  Lars Bäckman,et al.  Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. , 2005, Neuropsychology.

[36]  Alex Kiss,et al.  Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years , 2005, Neurology.

[37]  L. Thal,et al.  Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. , 1999, Psychology and aging.

[38]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[39]  C. Kawas,et al.  Learning and retention in preclinical and early Alzheimer's disease. , 1997, Psychology and aging.

[40]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[41]  Peter Davies,et al.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.

[42]  L. Wolfson,et al.  Clinico‐pathologic studies in dementia , 1988, Neurology.

[43]  P. Yates,et al.  Serotonin nerve cells in Alzheimer's disease. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[44]  W. Bondareff,et al.  Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia , 1982, Neurology.

[45]  T. Penzel,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2020, Springer Reference Medizin.

[46]  W. Sturm,et al.  Neuropsychological assessment , 2007, Journal of Neurology.